On the other hand, subgroups of HNSCC patients with activating, or gain-of-function NOTCH1 mutations have been observed as well, and these may show worse prognosis than tumours with wild-type NOTCH16. This evidence concerns the gene NOTCH1 and head and neck squamous cell carcinoma.